| Literature DB >> 31058874 |
Dongwon Hwang1, Minsun Kim2, Hyejin Park3, Myung In Jeong4, Woojin Jung5, Bonglee Kim6.
Abstract
Recent findings have shown great potential of alternative interventions such as immunotherapy and natural products for acute myeloid leukemia (AML). This study aims to review the anti-AML effect of various natural compounds. Natural compounds were classified into five groups: alkaloids, carotenoids, nitrogen-containing compounds, organosulfur compounds or phenolics based on each compound's chemical properties. Fifty-eight studies were collected and reviewed in this article. Phenolics are the most abundant group to have an apoptotic effect over AML cells, while other groups have also shown significant apoptotic effects. Some compounds induced apoptosis by regulating unique mechanism like human telomerase reverse transcriptase (hTERT) or laminin receptor (67LR), while others modified caspases, poly (adp-ribose) polymerase (PARP) and p53. Further study is required to identify side-effects of potent compounds and the synergistic effects of combination of two or more natural compounds or existing conventional anti-AML drugs to treat this dreadful disease.Entities:
Keywords: acute myeloid leukemia; alkaloids; apoptosis; carotenoids; natural products; nitrogen-containing compounds; organosulfur compounds; phenolics
Mesh:
Substances:
Year: 2019 PMID: 31058874 PMCID: PMC6567155 DOI: 10.3390/nu11051010
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Classification of phytochemicals [7].
Figure 2Review design flowchart.
Alkaloids.
| Classification | Compound | Source | Cell Line/Animal Model | Dose/Duration | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Alkaloids | 4′-methoxy-5-epi-ancistecrorine A1 |
| HL-60 | IC50 3.8–6.2 μM | [ | |
| Alkaloids | Canthin-6-one | Various plant genera and from fungi | Kasumi-1 | 45 μM; 24 h | c-capase-3, -8, -9, ROS, ASK-1, p38, JNK, CHK2, p53, H2A.X, p16, INK4A, p27-Kip1 ↑ | [ |
| MMP, p-RB ↓ | ||||||
| Alkaloids | Curine |
| HL-60 | 15 μM; 48h | MMP ↓ | [ |
| Alkaloids | Indicaxanthin | Cactus pear fruit | THP-1 | 13.5, 15, 15.5, 15.9, 16 µM (16 mM-7-KC); 12, 24 h | c-caspase-3, c-PARP-1, free intracellular Ca2+ ↑ | [ |
| Ik-Bα ↓ | ||||||
| Alkaloids | Intermedin A |
| HL-60 | 23.57 ± 2.15 µg/Ml; 12 h | c-caspase-3, c-PARP ↑ | [ |
| Alkaloids | Polyclonal anti-T-lymphocyte globulins | Rabbit ATG- Fresenius® | HL-60 | KG1: 100, 200, 300, 400, 500 μg/mL; 6 h | GVHD prophylaxis ↑ | [ |
| KG-1 | U937: 100, 200, 300, 400, 500 μg/mL; 6 h | |||||
| U937 | ||||||
| Alkaloids | Thalicultratine C |
| HL-60 | 0.06, 0.3, 1.5 μM; 24, 48, 72 h | MMP ↓ | [ |
Cleaved caspase (c-caspase); reactive oxygen species (ROS); apoptosis signal-regulating kinase 1 (ASK-1); p38 mitogen-activated kinase (p38); c-Jun N-terminal kinase (JNK); checkpoint kinase 2 (CHK2); tumor suppressor p53 (p53); H2A histone family member X (H2A.X); cyclin-dependent kinase inhibitor 2A (p16); inhibitors of CDK4A (INK4A); p27-Kip1 (cyclin-dependent kinase inhibitor 1B); mitochondrial membrane potential (MMP); retinoblastoma gene product (p-RB); cleaved poly ADP-ribose polymerase 1 (c-PARP-1); nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Ik-Bα); graft-versus-host disease (GVHD); ↑—up-regulation; ↓—down-regulation.
Carotenoids.
| Classification | Compound | Source | Cell Line/Animal Model | Dose/Duration | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Carotenoids | Aromatic (ar)-tumerone |
| U937 | 40, 80, 120 µg/mL; 48 h | Bax, c-caspase-3, cytochrome c, p53 ↑ | [ |
| Carotenoids | Fucoxanthin |
| HL-60 | 7.5, 15, 30 μg; 72 h | c-caspase-3, -7, c-PARP, ROS ↑ | [ |
| Bcl-xL ↓ | ||||||
| Carotenoids | Heteronemin | HL-60 | 5 nM; 72 h | AP-1, c-myc, MAPK, NF-κB, Ras ↑ | [ | |
| Carotenoids | Isolancifolide |
| HL-60 | HL-60: 25 μM; 2, 6, 12 h | c-caspase-8, -9, c-PARP ↑ | [ |
| Bid, pro-caspase-3, -8 ↓ |
Bcl-2-like protein 4 (Bax); cleaved caspase (c-caspase); tumor suppressor p53 (p53); cleaved poly ADP-ribose polymerase (c-PARP); reactive oxygen species (ROS); B-cell lymphoma-extra large (Bcl-xL); activator protein 1 (AP-1); mitogen-activated protein kinase (MAPK); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); Ras protein (Ras); BH3 interacting-domain death agonist (Bid); ↑—up-regulation; ↓—down-regulation.
Nitrogen-containing compounds.
| Classification | Compound | Source | Cell Line/Animal Model | Dose/Duration | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Nitrogen-containing compounds | Rhizochalin |
| THP-1 | 10, 20 mM; 6, 24 h | p53 ↑ | [ |
Tumor suppressor p53 (p53); ↑—up-regulation; ↓—down-regulation.
Organosulfur compounds.
| Classification | Compound | Source | Cell Line/Animal Model | Dose/Duration | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Organosulfur compounds | Asterosaponin |
| HL-60 | 0.01, 0.1, 1, 10, 50, 100 µM; 72 h | Bax, c-caspase-3, -9, c-PARP ↑ | [ |
| AKT, Bcl-2, c-myc, ERK 1/2, MAPK, PI3K ↓ | ||||||
| Organosulfur compounds | Chaetocin | HL-60 | 0.3 μM; 4, 24 h | c-caspase-3, -8 ↑ | [ | |
| Organosulfur compounds | Diallyl disulfide (DADS) |
| U937 | 25, 50, 100, 150 μM; 24 h | c-myc, Mad1, Sp-1 ↑ | [ |
| hTERT ↓ |
Bcl-2-like protein 4 (Bax); cleaved caspase (c-caspase); cleaved poly ADP-ribose polymerase (c-PARP); B-cell lymphoma 2 (Bcl-2); extracellular signal-regulated kinase 1, 2 (ERK1/2); mitogen-activated protein kinase (MAPK); phosphoinositide 3-kinase (PI3K); mitotic arrest deficient 1 (Mad1); Sp1 transcription factor (Sp-1); human telomerase reverse transcriptase (hTERT); ↑—up-regulation; ↓—down-regulation.
Phenolics.
| Classification | Compound | Source | Cell Line/Animal Model | Dose/Duration | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Phenolics | Epigallocatechin-3- | Green tea | HL-60 | 50, 100, 150, 200, 250 μg; 24 h | 67LR ↓ | [ |
| Phenolics | Vitisin B | HL-60 | HL-60: 12.5, 25 μM; 24, 36, 48 h | Bax, c-caspase-3, -8, -9, c-PARP, FasL, JNK ↑ | [ | |
| Phenolics | (R)-5-hydroxy-2-methylchroman-4-one (HMC) | HL-60 | 10, 20, 30 µg/mL; 48 h | c-caspase-3, -8, -9, c-PARP-1, CDK1, Cyclin A, cytochrome c, p21, p53, PUMA ↑ | [ | |
| Bax, Bcl-2, Bcl-xL, Bid, c-IAP-1, c-myc, cyclin D1, MMP, STAT3, survivin, VEGF ↓ | ||||||
| Phenolics | (8)-shogaol | Ginger | HL-60 | 30 µM | c-caspase-3, -9, c-DFF-45, c-PARP, ROS ↑ | [ |
| Bid, glutathione, MMP, pro-caspase-8 ↓ | ||||||
| Phenolics | 5-hydroxy-6,7,3′,4′,5′-pentamethoxyflavone |
| U937 | 10 μg/mL; 24 h | [ | |
| Phenolics | Alternariol-10-methyl ether |
| HL-60 | 100, 200 µM; 72 h | c-caspases ↑ | [ |
| MMP ↓ | ||||||
| Phenolics | Anthraquinone | HL-60 | 25, 50, 100, 200 μg/mL; 48 h | c-caspase-3, -8, -9 ↑ | [ | |
| Phenolics | Bergenin |
| HL-60 | HL-60: 1–100 μM; 48 h | cytochrome P450 ↓ | [ |
| Phenolics | Bigelovin | U937 | 1 µM; 24, 48 h | [ | ||
| Phenolics | Camphene |
| HL-60 | 167.75 µg/mL; 24 h | c-caspase-3, -7 ↑ | [ |
| Phenolics | Cantharidic acid |
| HL-60 | 10 μM; 24 h | c-caspase-3, -8, -9, c-PARP, JNK, p38 ↑ | [ |
| Phenolics | Capillin |
| HL-60 | 2 μM; 6 h | cytochrome c, ERK1/2, JNK ↑ | [ |
| IC50 6.5 ± 2.9 µM | ||||||
| AP-1, MAPK, NF ↓ | ||||||
| Phenolics | Carnosic acid | HL-60 | HL-60: 10, 15, 20 μM/L; 24–48 h | c-caspase-9, p27, PTEN ↑ | [ | |
| p-AKT, p-BAD ↓ | ||||||
| Phenolics | Casticin | HL-60 | 30, 40, 50 μg/mL; 24 h, 48 h | p-Histone H3 ↑ | [ | |
| Phenolics | Celastrol |
| HL-60 | 0.5 μM; 24 h | Bax, c-caspase -3, -9, p53 ↑ | [ |
| DHODH, uridine ↓ | ||||||
| Phenolics | Corchorusin-D |
| HL-60, U937 | HL-60: 25, 50, 75, 100, 120, 150 μg/mL; 24 h | Bax ↑ | [ |
| U937: 50, 75, 100, 125, 150 μg/mL; 24 h | Bcl-2, MMP ↓ | |||||
| Phenolics | Costunolide |
| U937 | 10 µM; 0.5, 1,2 h | Bcl-2, p-ERK1/2, p-JNK ↑ | [ |
| Bcl-2, ROS ↓ | ||||||
| Phenolics | Coumarin |
| HL-60 | HL-60: 5 μM; 24, 48 h | Bax, c-caspase -3, -9, c-PARP ↑ | [ |
| Bcl-2, c-myc, p-AKT, p-ERK1/2 ↓ | ||||||
| Phenolics | Cucurbitacin E |
| HL-60 | 1–10 mol/L | Bax ↑ | [ |
| IAP, Mcl-1, survivin ↓ | ||||||
| Phenolics | Curcumin | turmeric | THP-1 | 50 μM; 3, 6, 12 h | c-caspase-3, -8, -9, c-PARP-1, JNK, p-ERK ↑ | [ |
| Phenolics | Erypoegin K |
| HL-60 | 0.175 ± 0.004 μM; 48h | c-caspase-3 ↑ | [ |
| 10 μM; 24h | ||||||
| Phenolics | Furanodiene |
| HL-60 | 10, 30, 50, 70 μM; 6 h | Bid, c-caspase-3, -8, -9, c-PARP, TNFα ↑ | [ |
| Phenolics | Gallic acid |
| U937 | 5.8, 58, 580 µM; 24 h | p53, NF-κB, ↑ | [ |
| GAPDH, I-κB ↓ | ||||||
| Phenolics | Ginsenoside Rh2 | KG-1 | 100, 200, 300, 400, 500 μg/mL; 6 h | c-caspase-3, p21, p53 ↑ | [ | |
| Phenolics | Ginsenoside Rh2 |
| HL-60, U937 | HL-60: 10, 20, 30 μM; 24, 48, 72 h | p21, p27 ↑ | [ |
| U937: 10, 20, 30 μM; 24, 48, 72 h | CDK4, CDK6, Cyclin D1, Cyclin D2, Cyclin D3, Cyclin E ↓ | |||||
| Phenolics | Glaucocalyxin A | HL-60 | 10.0 μg/mL; 24 h | Bax, c-caspase-3, -9 ↑ | [ | |
| Bcl-2 ↓ | ||||||
| Phenolics | Icariside D2 | HL-60 | IC50 9.0 ± 1.0 µM; 72h | Bax, c-caspase -3 ↑ | [ | |
| 9.0 µM; 24, 48 h | Bcl-2, c-myc, c-PARP, p-AKT ↓ | |||||
| Phenolics | Icariside II |
| U937 | 25, 50 μM; 24, 48, 72 h | c-caspase-3, c-PARP, PTP, SHP-1 ↑ | [ |
| Bcl-2, Bcl-X, COX-2, JAK2, Src, STAT3, survivin ↓ | ||||||
| Phenolics | Isochamaejasmin | HL-60 | HL-60: IC50 50.40 ± 1.21 μmol·L−1 25 and 50 μmol·L−1; 48 h | c-caspase-3, -9, c-PARP ↑ | [ | |
| Bcl-2 ↓ | ||||||
| K562: IC50 24.51 ± 1.62 μmol·L−1 | ||||||
| Phenolics | Karanjin |
| HL-60 | 2, 4, 6 µM; 72 h | [ | |
| Phenolics | MMH01 |
| U937 | 5, 10 µg/mL; 24 h | Bax, Bcl-2, Chk2, Cyclin B1 ↑ | [ |
| Phenolics | Phanginin D | HL-60 | 10, 30 µM; 24, 48 h | c-caspase-3 ↑ | [ | |
| Phenolics | PO-1 |
| HL-60 | IC50 8.9 μM; 72 h | α-tubulin, Cdc2, FAK, JunB, MYPT, NF-κB ↑ | [ |
| 25, 50, 100 μM; 24, 48, 72 h | CCID, Cdc25A, Chk2, MCF-7 ↓ | |||||
| Phenolics | Proanthocyanidins | 11 berry species | THP-1 | 50 μg/mL; 24 h | c-caspase 8 ↑ | [ |
| Phenolics | Shikonin |
| HL-60 | 1, 2, 5 μM; 24, 48 h | ROS, c-caspase-3 ↑ | [ |
| Phenolics | Shikonin |
| HL-60 | 2.5 µM; 24 h | ATF6, calreticulin, CHOP, ERp57, IRE-1 ↓ | [ |
| Phenolics | Silvestrol |
| THP-1 | 50 nm; 24 h | FLT3, miR-155 ↓ | [ |
| Phenolics | Tanshinone I | HL-60 | 31 ± 7.1 μmol/L; 24 h, | Bax ↑ | [ | |
| 22 ± 7.6 μmol/L; 48 h, | ||||||
| c-caspase-3, survivin ↓ | ||||||
| 15 ± 4.3 μmol/L; 72 h | ||||||
| Phenolics | Tanshinone IIA |
| U937 | 2, 3, 5, 10 µg/mL; 12 h, 24, 36, 48 h | c-caspase 3, PXR ↑ | [ |
| CCL2, NF-κB ↓ | ||||||
| Phenolics | Wogonin | HL-60 | 10 μM; 24h | [3H]etoposide ↑ | [ | |
| P-gp ↓ | ||||||
| Phenolics | Wogonin |
| HL-60 | 10 mg/mL; 20, 25, 30, 35, 40 min | c-caspase-3 ↑ | [ |
| Bcl-2, c-myc, telomerase ↓ | ||||||
| Phenolics | Xanthatin |
| HL-60 | HL-60: 100 μg/mL; 48 h | c-caspase-3, -7 ↑ | [ |
| PGE2 ↓ | ||||||
| Phenolics | β-mangostin |
| HL-60 | 58 µM; 24 h | Bax, c-caspase -3, -9, cytochrome c, p53 ↑ | [ |
| Bcl-2, HSP70 ↓ |
67 kDa laminin receptor (67LR); bcl-2-like protein 4 (Bax); cleaved caspase (c-caspase); cleaved poly ADP-ribose polymerase (c-PARP); first apoptosis signal ligand (FasL); c-Jun N-terminal kinase (JNK); cyclin dependent kinase 1 (CDK1); cyclin-dependent kinase inhibitor 1 (p21); tumor suppressor p53 (p53); p53 upregulated modulator of apoptosis (PUMA); B-cell lymphoma 2 (Bcl-2); B-cell lymphoma-extra large (Bcl-xL); BH3 interacting-domain death agonist (Bid); cellular inhibitor of apoptosis protein 1 (c-IAP-1); mitochondrial membrane potential (MMP); signal transducer and activator of transcription 3 (STAT3); vascular endothelial growth factor (VEGF); cleaved DNA fragmentation factor 45 (c-DFF-45); reactive oxygen species (ROS); p38 mitogen activated protein (p38); extracellular signal-regulated kinase 1, 2 (ERK1/2); activator protein 1 (AP-1); mitogen-activated protein kinase (MAPK); nuclear factor (NF); cyclin-dependent kinase inhibitor 1B (p27); phosphatase and tensin homolog (PTEN); phospho-protein kinase B (p-AKT); phospho-Bcl-2 associated death (p-BAD); phospho-histone H3 (p-Histone H3); dihydroorotate dehydrogenase (DHODE); phospho-extracellular signal-regulated kinase 1, 2 (p-ERK1/2); phospho-c-Jun N-terminal kinase (p-JNK); inhibitor of apoptosis protein (IAP); myeloid cell leukemia 1 (Mcl-1); tumor necrosis factor alpha (TNFα); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); glyceraldehyde 3-phosphate dehydrogenase (GAPDH); cyclin dependent kinase (CDK); protein tyrosine phosphatase (PTP); Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1); B-cell lymphoma X (Bcl-X); cyclooxygenase 2 (COX-2); Janus kinase 2 (JAK2); Src family of the tyrosine kinases (Src); signal transducer and activator of transcription 3 (STAT3); checkpoint kinase 2 (Chk2); cell division control 2 (Cdc2), focal adhesion kinase (FAK), JunB proto-oncogene (JunB); myosin phosphatase targeting protein (MYPT); cell culture infectious dose (CCID); M-phase inducer phosphatase 1 (Cdc25A); activating transcription factor 6 (ATF6); CCAAT-enhancer-binding protein homologous protein (CHOP); protein disulfide-isomerase A3 (ERp57); inositol-requiring enzyme 1 (IRE-1); fms like tyrosine kinase 3 (FLT3); micro RNA 155 (miR-155); pregnane X receptor (PXR); C-C Motif Chemokine ligand 2 (CCL2); P-glycoprotein (P-gp); prostaglandin E2 (PGE2); heat shock protein 70 (HSP70); ↑—up-regulation; ↓—down-regulation.